Atacand
(candesartan)ApprovedSmall molecule
AstraZenecaCandesartan is a blood pressure medication that relaxes blood vessels to help blood flow more easily and allows the heart to pump more efficiently. It's used to treat high blood pressure and heart failure.[2] Atacand is currently approved and in use across 35 indications[4].[1]
Atacand is one of 783 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
35
Indications
68
Total Trials
5
Active Trials
782
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 34 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Atacand
AstraZenecaApproved
Trodelvy
GileadPreclinical
Avastin
BBio-Thera Solutions
Preclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Voltaren
NovartisPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Avastin
RochePreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertension6 trials
Heart Failure6 trials
Show 3 more trials
Interaction4 trials
ART3 trials
40 more indications
Function2 trials
Aortic Stenosis2 trials
Double-blind2 trials
Diabetic Retinopathy2 trials
Migraine2 trials
Tics2 trials
Dilated Cardiomyopathy1 trial
Chronic Hepatitis1 trial
Clinical Trial1 trial
Diabetes Mellitus1 trial
Cardiovascular Events1 trial
Hypertrophic Cardiomyopathy1 trial
CHANCE - Candesartan in Hypertrophic Cardiomyopathy
Unknown status·—·Phase 2·NCT00430833
Combination Therapy1 trial
Essential Hypertension1 trial
Fasting Conditions1 trial
Efficacy and Safety1 trial
Single Dose1 trial
Angiotensin Converting Enzyme1 trial
Atrial Fibrillation1 trial
Candesartan in the Prevention of Relapsing Atrial Fibrillation
Completed·—·Phase 3·NCT00130975·200 enrolled
Stroke1 trial
Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST)
Unknown status·—·Phase 4·NCT00108706·50 enrolled
Cognitive Function1 trial
Cardiotoxicity1 trial
Methamphetamine Dependence1 trial
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
Completed·—·Phase 1·NCT01062451·80 enrolled
Adiposity1 trial
Adiposity and Endothelin Receptor Function
Active, not recruiting·—·Phase 1·NCT03583866·25 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Atacand drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for candesartan. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Type-1 Angiotensin II Receptor Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company